Aquoral Oral Spray Lands on CareQuest’s 2026 Innovation Map

K Pharmaceuticals said Aquoral Protective Oral Spray was named one of five dry-mouth products in CareQuest Innovation Partners’ 2026 Oral Health Innovation Market Map. The recognition highlights growing demand for treatments that fit into existing care workflows and offer longer relief for a condition affecting more patients.

Why it matters: - CareQuest Innovation Partners’ recognition puts Aquoral in a small group of dry-mouth products singled out for innovation. - Dry mouth is becoming a broader care issue as prevalence rises and more patients look for relief that is practical, durable and easy to deliver in clinical settings. - The report’s emphasis on workflow integration and measurable value matters for products trying to move beyond symptom relief and into routine care.

What happened: - K Pharmaceuticals said Aquoral Protective Oral Spray was included as one of five products in CareQuest Innovation Partners’ 2026 Oral Health Innovation Market Map. - The announcement was dated Oct. 15, 2026, from Phoenix. - CareQuest Innovation Partners, together with CareQuest Institute for Oral Health, focuses on improving overall health through oral health and bridging gaps between medical and dental care.

The details: - Aquoral uses a patented, lipid-based formula with Oxidized Glycerol Triesters technology. - The spray coats the oral mucosa and forms a protective barrier. - K Pharmaceuticals said the product can provide relief for up to 6 hours, including during eating and drinking. - The company contrasted Aquoral with OTC aqueous-based dry-mouth products, which it said have not delivered long-lasting relief for many patients. - K Pharmaceuticals also contrasted Aquoral with prescription options that can bring unwanted side effects. - The company said dry mouth has become more common because of polypharmacy, 1,100 medications with dry mouth as a side effect, GLP-1 therapies, CPAP machines, sleep appliances, tobacco, alcohol and recreational drugs such as marijuana. - The company said dry mouth was once viewed mainly as a condition affecting older adults and patients with Sjogren’s disease, head and neck cancer, or radiation treatment. - K Pharmaceuticals said it offers educational training, clinical support, a treatment protocol, a wholesale stocking program and a patient assistance program for eligible patients. - The company said the stocking program is designed to close gaps in care so patients can leave the office with a dry-mouth treatment. - Bennett Blakeman, CEO of K Pharmaceuticals, said dry mouth can make it difficult for patients to swallow, chew, taste, speak or sleep. - Blakeman said patients describe Aquoral as a “game changer” and value the longer-lasting relief.

Between the lines: - The recognition suggests the market for dry-mouth products is shifting from simple symptom management toward integrated care solutions. - CareQuest’s criteria point to a bigger hurdle than product performance: providers need something that can fit into existing office routines and prove value. - K Pharmaceuticals is framing Aquoral not just as a consumer product, but as a clinic-ready option with support services built around adoption.

What's next: - K Pharmaceuticals is likely to use the CareQuest recognition to push broader provider awareness and office adoption. - The company’s workflow tools, stocking model and assistance program appear aimed at making Aquoral easier to prescribe, stock and dispense. - The full report is available as the 2026 Oral Health Innovation Market Map.

The bottom line: - Aquoral’s inclusion on CareQuest’s innovation map gives K Pharmaceuticals a third-party validation point in a fast-growing dry-mouth market that now rewards both clinical utility and care integration.